Valneva Shares at €2.70: Oversold RSI After a 38% Drop in Three Months
The stock of the Nantes-based vaccine specialist rose by 2.5% this Tuesday compared to the previous day, yet it does not offset a quarter of significant losses. Valneva is trading at €2.70, reflecting a nearly 38% decline over three months, in a Parisian market trending upwards with the CAC 40 up by 0.79% during the session.
Valneva's stock price stands at €2.70 in mid-afternoon, up 2.5% from the previous day's close of €2.64. This slight increase remains marginal compared to recent trends: the stock has lost 37.61% over three months and 2.52% over a year. The technical support identified at €2.58 held during recent sessions, partly explaining today's modest rebound. The RSI, a momentum indicator, is at 29, marking the threshold of the generally established oversold zone at 30. This level indicates that selling pressure has been particularly intense in recent weeks. Furthermore, the current price is significantly below the 50-day moving average (€4.00) and the 200-day average (€3.88), confirming a medium-term downward trend. At €2.70, the stock is in the lower part of the Bollinger Bands, at 33% of the range between the lower bound (€1.52) and the upper bound (€5.09).
Upcoming Financial Events and Sector Performance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Investors will gain a first glimpse of visibility on May 7, when Valneva is set to publish its first-quarter 2026 results. This event will be followed by the annual general meeting scheduled for June 1. These milestones could help clarify the operational and financial trajectory of the group, in a context where the stock has lost more than a third of its value in three months. On a European sector level, the session is mixed: Sanofi is up by 1.17% while UCB is down by 0.18%. Valneva's negative beta (-0.21) indicates an inverse correlation with the market, giving the stock an atypical profile within the Paris stock exchange. The half-year results, expected on August 13, will be another crucial milestone to assess the group's ability to stabilize its valuation.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.